Carbamazepine Treatment for Cocaine Dependence - 5

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000191
First received: September 20, 1999
Last updated: May 26, 2015
Last verified: May 2015
  Purpose
The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Carbamazepine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Carbamazepine Treatment for Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Estimated Enrollment: 0
Study Start Date: January 1991
Study Completion Date: February 1994
Primary Completion Date: February 1994 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   21 Years to 51 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000191

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

Publications:
Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000191     History of Changes
Other Study ID Numbers: NIDA-00144-5  3R01DA012268  K20-00144-5 
Study First Received: September 20, 1999
Last Updated: May 26, 2015
Health Authority: United States: Federal Government

Keywords provided by University of Pennsylvania:
Cocaine Dependence
Carbamazepine

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Carbamazepine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers

ClinicalTrials.gov processed this record on August 25, 2016